NASDAQ
09.12.24
21:59 Uhr
50,68 US-Dollar
0,00
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Tarsus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| 13.11. | Tarsus Pharmaceuticals GAAP EPS of -$0.61 beats by $0.31, revenue of $48.1M beats by $4.92M | 1 | Seeking Alpha | ||
| 13.11. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | 105 | GlobeNewswire (Europe) | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| 13.11. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Tarsus Pharmaceuticals, Inc: Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors | 2 | GlobeNewswire (USA) | ||
| 12.11. | Earnings Outlook For Tarsus Pharmaceuticals | 2 | Benzinga.com | ||
| 06.11. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 | 2 | GlobeNewswire (USA) | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled | 5 | Seeking Alpha | ||
| 06.11. | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch bei 48,65 US-Dollar | 2 | Investing.com Deutsch | ||
| 06.11. | Tarsus Pharmaceuticals stock hits 52-week high at $48.65 | 1 | Investing.com | ||
| 05.11. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Tarsus appoints Elizabeth Yeu as its Chief Medical Officer | 1 | Seeking Alpha | ||
| 05.11. | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | 80 | GlobeNewswire (Europe) | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen | |
| 29.10. | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | 2 | Investing.com | ||
| 29.10. | Tarsus Pharmaceuticals gains amid takeover speculation | 13 | Seeking Alpha | ||
| 22.10. | Oppenheimer hält an Kursziel und Outperform-Rating für Tarsus trotz Umsatzprognose fest | 3 | Investing.com Deutsch | ||
| 22.10. | Oppenheimer retains stock target, outperform on Tarsus amid sales projection | 1 | Investing.com | ||
| 17.10. | Tarsus taps actor Betsy Sodaro to embody a 'mitey problem' in 1st Xdemvy DTC TV ad | 2 | FiercePharma | ||
| 17.10. | Tarsus Pharmaceuticals, Inc: Tarsus Launches "Your Mitey Problem," the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% | 1 | GlobeNewswire (USA) | ||
| 04.10. | Guggenheim behält Kaufempfehlung für Tarsus-Aktien bei - Xdemvy-Markteinführung überzeugt | 3 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,570 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,356 | +0,85 % | Defence Therapeutics Inc.: Defence Provides Update on Delivery of AGSM Proxy Materials | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 10,300 | +0,98 % | Ginkgo Bioworks-Führungskraft veräußert Aktien im Wert von 3.182 US-Dollar | ||
| PHIO PHARMACEUTICALS | 2,720 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 8,450 | -0,24 % | Peering Into Iovance Biotherapeutics' Recent Short Interest | ||
| RECURSION PHARMACEUTICALS | 8,265 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,490 | +2,92 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 13,185 | +0,57 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| ONCOLYTICS BIOTECH | 0,835 | +0,60 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,830 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,938 | -0,38 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,945 | -0,36 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,010 | 0,00 % | Looking Into ADMA Biologics' Recent Short Interest | ||
| VIR BIOTECHNOLOGY | 8,720 | 0,00 % | Vir Biotechnology EVP Vanina de Verneuil verkauft Aktien im Wert von 624 US-Dollar | ||
| VERVE THERAPEUTICS | 7,180 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen |
Das Unternehmen TARSUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 50,68 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
